Rheumatoid Arthritis Therapeutics

Rheumatoid Arthritis Therapeutics published by Global Industry Analysts, Inc. in February, 2010. This report consists of Pages: 824 and the price starts from US $ 3950.

Introduction

Abstract

This report analyzes the worldwide markets for Rheumatoid Arthritis Therapeutics in US$ Million.The report provides separate comprehensive analytics for US, Japan, Europe, Latin America and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. The report profiles 103 companies including many key and niche players worldwide such as Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co., Ltd., Genentech Inc., Genmab AS, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Schering-Plough Corp., UCB S.A., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW & OUTLOOK

• Global Pharmaceutical Industry Hit by Economic Downturn
• Credit Crunch to Affect Biological Drug Pipeline
• Biotech Bankruptcies Rife in the Current Economic Downturn
• Economic Downturn Takes Toll on R&D
• Autoimmune Disease Therapeutics - An Ever Flourishing Market
• Rheumatoid Arthritis - A Chronic, Debilitating Disease
• Incidence and Prevalence Higher in Urban and Developed Regions
• Rheumatoid Arthritis - Market Overview
• A Look At Arthritis Market Sales Data
• Table 1: World Arthritis Market - Value Sales of Drug Classes for 2006 and 2007 (USD billion) (includes corresponding Graph/Chart)
• Table 2: World Arthritis Market - Value Sales of Anti- TNF Biologics for 2007 (USD billion) (includes corresponding Graph/Chart)
• Table 3: World Arthritis Market -Value Sales of Select NSAIDs for 2007 (USD billion) (includes corresponding Graph/Chart)
• Table 4: World Arthritis Market - Value Sales of COX-2 Inhibitors for 2007 (USD billion)
• Market Outlook
• Global Market Estimates and Forecasts

2. MARKET DYNAMICS AND TRENDS

• Anti-TNF Biologic Therapies - The Market Leading RA Drugs
• Table 5: World Rheumatoid Arthritis Market - Value Sales* of Biologic Response Modifiers: 2007 and 2008 (in US$ Billion) (includes corresponding Graph/Chart)
• Biologics Continue to Gain Market Share
• Expensive Biologics to Drive Value Growth
• Year of Approval of Leading Biologics in Rheumatoid Arthritis Therapy
• New Products to Drive Market Growth
• Superior Outcomes to Enhance Adoption of Biologics
• Efficacy and Convenience - Key Factors Driving Physician' s Decision
• Non-Anti-TNFs, Orencia to Gain Strength
• Patent Expiry - A Mid- to Long-term Threat
• Year of Expected Generic Market Entry of Leading Biologics in Rheumatoid Arthritis Therapy
• Competitive Landscape
• Table 6: Comparative Analysis of Leading Biologic Rheumatoid Arthritis Drugs based on ACR Scores by End Point (includes corresponding Graph/Chart)
• High Prices and Safety Concerns

3. RHEUMATOID ARTHRITIS: THE DISEASE AND

• Arthritis
• Rheumatoid Arthritis
• The Disease Progression
• The Age Factor
• Causes and Diagnosis
• Signs and Symptoms
• Treatment
• Non-steroidal Anti-inflammatory Drugs
• Side Effects Profile
• Cyclo-Oxygenase-2 Inhibitors
• Celecoxib
• Others
• Anti-rheumatic Steroids
• Side Effects Profile
• Corticosteroids
• Glucocorticoids
• Disease-modifying Anti-rheumatic Drugs (DMARDs)
• D-penicillamine
• Gold Salts
• Hydroxychloroquine
• Leflunomide
• Methotrexate
• Sulfasalazine
• Others
• Biological Response Modifiers
• Adalimumab (Humira)
• Etanercept
• Infliximab
• Anakinra
• Abatacept
• Rituximab
• Tocilizumab

4. DRUG DEVELOPMENT FOCUS

• The Rheumatoid Arthritis Pipeline
• List of Select RA Drug Candidates in Various Clinical Pipeline Phases: 2008-09
• Opportunities Aplenty for New Oral Agents in RA Treatment

5. RESEARCH & DEVELOPMENT

• Velcura to Commence Clinical Trials for Lead Rheumatoid Arthritis Compound
• Biogen Announces Phase II Trial Results for Baminercept in Rheumatoid Arthritis
• Genentech, Biogen Announce Encouraging Phase III Results of Rituxan
• Chelsea Announces Encouraging Preclinical Results for RA Drug Candidate
• Medarex Commences Phase II Trials for Rheumatoid Arthritis Treatment Drug
• ChemoCentryx Launches Phase I Clinical Trial for CCR1 Inhibitor
• Chelsea Commences Phase II Trial for CH-1504
• Arana Therapeutics Initiates Phase II Trial of ART621 in Rheumatoid Arthritis
• VGX Pharma Initiates Follow-on Phase I Study for VGX-1027
• Genmab to Commence Phase I/II Trial of Ofatumumab in RA Patients
• Can-Fite Announces Seikagaku' s Proposed Phase I Trial for CF101 in Japan
• Hollis-Eden Pharma Initiates Phase I/II Trial of Triolex in RA Patients
• Trubion Pharma Announces Initiation of Phase 1 Trial of SBI-087
• Micromet and Nycomed Initiate Formal Preclinical Safety Studies

6. RECENT INDUSTRY ACTIVITY

• GlaxoSmithKline Forms Strategic Alliance with Archemix
• Cypress Bioscience Acquires Proprius Pharmaceuticals
• Biotie to Takeover German Company, elbion
• Roche to Acquire UK Company, Piramed
• Pipex Acquires Rheumatoid Arthritis Drug Candidate, dnaJP1
• Latona Signs Two Agreements to Acquire Orphan Drug Status and Patent Rights
• MorphoSys, Galapagos Sign Alliance to Co-Develop Antibody Therapies
• Nycomed Inks Agreement with Immunomedics for Veltuzumab
• Affitech Signs Antibody Discovery and Development Deal with Omeros
• Entelos Signs Research Agreement with UCB Pharma
• Novo Nordisk and VLST Form Partnership to Develop Therapeutic Targets
• Maxygen Enters into Agreement with Astellas for MAXY-4
• GlaxoSmithKline Forms Global Alliance with Regulus Therapeutics
• Can-Fite Signs License Agreement with Korean Company for RA Drug
• Amgen, Wyeth Announce U.S. Prescribing Information Update for Enbrel
• Galapagos Secures Grant for Rheumatoid Arthritis Drug Development
• MorphoSys and University of Melbourne to Receive U.S. Patent
• Merrimack Acquires Funds for Developing Biologics
• Galapagos Announces GT146 Milestone Achievement
• Amgen Acquires Avidia
• Iroko Acquires Two Pharmaceutical Products from Merck
• EvoGenix to Merge with Peptech
• Eli Lilly and MacroGenics Tie Up for Developing Teplizumab
• Pharmacopeia and Wyeth Sign R&D Agreement to Develop JAK3 Inhibitors
• Nuon Enters into Strategic Agreement with Kissei Pharmaceutical
• Roche and Toyama Enter into Licensing Agreement for T-5224
• GSK and Genmab Sign Partnership Agreement for HuMaxCD20

7. PRODUCT APPROVALS / APPLICATIONS

• UCB Receives FDA Approval for Cimzia for Treating Rheumatoid Arthritis
• Centocor Announces FDA Approval of Simponi(tm) for Rheumatoid Arthritis
• Chugai Announces Japanese Approval of Actemra for RA Treatment
• Abbott Secures Japanese Approval for Humira for RA Treatment
• Chugai and Roche Secure Swiss Approval for RoACTEMRA
• Chugai and Roche Announce Further FDA Guidance on BLA for Actemra
• Roche, Chugai Announce CHMP' s Positive Recommendation for RoActemra
• Roche' s Actemra Recommended for Approval by FDA Advisory Committee
• Centocor, Schering-Plough Submit MAA for Golimumab Approval
• UCB Submits MAA to the EMEA for Approval of Certolizumab Pegol
• Abbott Secures FDA Approval for Humira for Polyarticular JIA Treatment
• Xian-Janssen Introduces Remicade, Branded infliximab in China
• Abbott Files for Humira Approval as JRA Treatment in the US and Europe
• Roche Receives NICE Approval for MabThera as Severe RA Treatment

8. FOCUS ON SELECT PLAYERS

• Abbott Laboratories, Inc. (USA)
• Amgen, Inc. (USA)
• Biogen Idec, Inc. (USA)
• Bristol-Myers Squibb Company (USA)
• F. Hoffmann-La Roche AG (Switzerland)
  • Chugai Pharmaceutical Co., Ltd. (Japan) - A Member of Roche Group
  • Genentech Inc. (USA)
  • Genmab AS (Denmark)
  • GlaxoSmithKline PLC (UK)
  • Johnson & Johnson Services, Inc. (USA)
  • Schering-Plough Corp. (USA)
  • UCB S.A. (Belgium)
  • Wyeth (USA)

9. GLOBAL MARKET PERSPECTIVE

• Table 7: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region - US, Japan, Europe, Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 8: World 10-Year Perspective for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region - Percentage Breakdown of Dollar Revenues for the US, Japan, Europe, Latin America and Rest of World Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

• A. Market Analysis
  • Current & Future Analysis
  • Rheumatoid Arthritis - Prevalence
  • Table 9: US Rheumatoid Arthritis Patient Group Breakdown for 2008 (includes corresponding Graph/Chart)
  • Table 10: US Moderate to Severe Rheumatoid Arthritis Patient Group Breakdown by Therapy for 2008 (includes corresponding Graph/Chart)
  • Market Overview
  • Market Trends
  • Biologic Drugs Lead the Fray
  • Table 11: US Rheumatoid Arthritis Therapeutics Market -Breakdown of Value Sales of Leading Biologic Therapies for 2007 (includes corresponding Graph/Chart)
  • Enbrel and Humira Continue to Gain Share in the Anti-TNF Market
  • Research and Development
  • Strategic Corporate Developments
  • Product Approvals
  • Select Players
• B. Market Analytics
  • Table 12: US Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) - Annual RevenueFigures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2. JAPAN

• A. Market Analysis
  • Current & Future Analysis
  • Market Overview
  • Table 13: Japanese Rheumatoid Arthritis Patient Group Breakdown for 2008 (includes corresponding Graph/Chart)
  • Research and Development
  • Strategic Corporate Developments
  • Product Approvals
  • Select Player
• B. Market Analytics
  • Table 14: Japanese Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) - Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3. EUROPE

• A. Market Analysis
  • Current & Future Analysis
  • Rheumatoid Arthritis - Prevalence
  • Table 15: European Rheumatoid Arthritis Patient Group Breakdown for 2008 (includes corresponding Graph/Chart)
  • Market Overview
  • Research and Development
  • Strategic Corporate Developments
  • Product Approvals
  • Select Players
• B. Market Analytics
  • Table 16: European Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) - Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

4. LATIN AMERICA

• A. Market Analysis
  • Current & Future Analysis
• B. Market Analytics
  • Table 17: Latin American Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) by Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 18: Latin American 10-Year Perspective for Rheumatoid Arthritis Therapeutics by Region - Percentage Breakdown of Dollar Revenue for Brazil and Rest of Latin America Markets for 2006, 2009 & 2015

5. REST OF WORLD

• A. Market Analysis
  • Current & Future Analysis
  • Canada
  • Canadian Rheumatoid Arthritis Therapeutics Market
  • Australia
  • Overview of Rheumatoid Arthritis in Australia
  • Table 19: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Age Group (includes corresponding Graph/Chart)
  • Table 20: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Gender (includes corresponding Graph/Chart)
  • Research and Development
  • Strategic Corporate Developments
  • Product Launch
• B. Market Analytics
  • Table 21: Rest of World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics)- Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Related Reports